Hua Medicine
02552
Company Profile
Business description
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from PRC.
Contact
Lane 36, Xuelin Road
Hua Medicine, Building 2
Pudong New Area
Shanghai201203
CHNT: +86 2138101800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
285
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.70 | 39.80 | -0.44% |
| CAC 40 | 7,749.39 | 14.55 | 0.19% |
| DAX 40 | 23,718.45 | 88.68 | -0.37% |
| Dow JONES (US) | 45,711.34 | 196.39 | 0.43% |
| FTSE 100 | 9,242.53 | 21.09 | 0.23% |
| HKSE | 25,938.13 | 304.22 | 1.19% |
| NASDAQ | 21,879.49 | 80.79 | 0.37% |
| Nikkei 225 | 43,459.29 | 184.52 | -0.42% |
| NZX 50 Index | 13,253.73 | 27.41 | -0.21% |
| S&P 500 | 6,512.61 | 17.46 | 0.27% |
| S&P/ASX 200 | 8,803.50 | 37.40 | -0.42% |
| SSE Composite Index | 3,807.29 | 19.55 | -0.51% |